Li-Fraumeni综合征合并早期乳腺癌患者放疗诱导恶性肿瘤的发生率及放疗技术的影响
本研究在单中心回顾48例携带TP53致病/可能致病变异且患早期乳腺癌的患者,评估辅助放疗后放疗野内放疗诱导恶性肿瘤(RIM)的发生率及其与放疗剂量和技术的关系。30例接受放疗的患者中10%发生RIM(3例软组织恶性肿瘤);RIM发生率2D放疗为100%(2/2)、IMRT为50%(1/2)、3D放疗为0%(0/16)(P = .004),放疗剂量(≤40.8或>40.8 Gy)未见影响。作者强调推荐放疗前应充分评估风险获益,尽可能避免放疗,并主张早期进行TP53检测以指导乳腺癌治疗方案。
要点
- 48例TP53变异早期乳腺癌患者中62%接受放疗,放疗后10%在照射野内发生RIM。
- RIM发生率2D放疗100%(2/2)、IMRT 50%(1/2)、3D放疗0%(0/16),差异有统计学意义(P = .004)。
- 放疗剂量≤40.8或>40.8 Gy未见影响RIM发生,作者认为应尽早行TP53检测以指导治疗。
核心结论
- 本研究提示辅助放疗后RIM发生率值得关注,作者强调推荐放疗前应进行充分的风险获益评估,并尽可能避免放疗。
- 作者认为尽管亚组样本量有限,RIM风险似乎受放疗技术影响,2D放疗和IMRT的发生率高于3D放疗。
- 作者指出早期TP53检测对指导乳腺癌治疗方案至关重要。
研究设计与样本
- 单中心 hereditary cancer team 随访的携带胚系TP53致病/可能致病变异并诊断为早期乳腺癌的患者。
- 共分析48例患者,中位年龄39岁(范围21-62岁)。
- 研究终点包括RIM发生率、RIM与放疗剂量及类型(2D放疗、3D放疗、IMRT)的关系以及乳腺癌复发。
主要发现
- 71%的患者携带TP53 R337H变异,87%在乳腺癌治疗时不知晓其LFS诊断。
- 治疗方式包括乳房切除术(62%)、(新)辅助化疗(66%)和放疗(62%),放疗在保乳术后更常见(87% vs 乳房切除术后46%,P = .010)。
- 30例接受放疗的患者中,10%在照射野内发生RIM,均为3例软组织恶性肿瘤。
- 放疗剂量(≤40.8或>40.8 Gy)未影响RIM发生,但放疗类型有影响。
- RIM发生率2D放疗为100%(2/2)、IMRT为50%(1/2)、3D放疗为0%(0/16)(P = .004)。
临床怎么用
- 作者强调推荐放疗前应进行充分的风险获益评估,并尽可能避免放疗。
- 作者指出早期TP53检测对指导乳腺癌治疗方案至关重要。
局限性
- 原文指出亚组样本量有限(subgroup sizes were limited)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Breast cancer (BC) is the most common malignancy in female patients with Li-Fraumeni syndrome (LFS), a condition associated with an increased risk of various malignancies, including radiation therapy (RT)-induced malignancies (RIM) within previously irradiated areas. Our study aimed to assess the incidence of RIM in patients with LFS and early-stage BC treated with adjuvant RT, including the effect of RT dose and technique. METHODS AND MATERIALS: We examined patients with a germline pathogenic/likely pathogenic TP53 variant diagnosed with early-stage BC and monitored by a hereditary cancer team at a single cancer center. The study endpoints included RIM frequency, the association of RIM with the dose and type of RT (2-dimensional [2D] RT, 3-dimensional [3D] RT, and intensity modulated RT [IMRT]), and BC recurrence. RESULTS: We analyzed 48 patients with a median age of 39 years (range, 21-62). The majority (71%) had the TP53 R337H variant, and 87% were unaware of their LFS diagnosis at the time of BC treatment. Treatment modalities included mastectomy (62%), (neo)adjuvant chemotherapy (66%), and RT (62%), with RT being more common after breast-conserving surgery (87% vs 46% with mastectomy, P = .010). Among the 30 patients treated with RT, 10% developed RIM in the irradiated field, consisting of 3 soft tissue malignancies. RT dose (≤40.8 or >40.8 Gy) did not influence RIM occurrence, but the type of RT did. RIM was observed in 100% of cases with 2D RT (2/2), 50% with IMRT (1/2), and 0% with 3D RT (0/16) (P = .004). CONCLUSIONS: Our study underscores a concerning rate of RIM after adjuvant RT, emphasizing the importance of a thorough risk-benefit evaluation before recommending RT, with preference for its avoidance if possible. Although subgroup sizes were limited, the risk of RIM appeared to be influenced by the RT technique, with higher rates observed with 2D RT and IMRT compared with 3D RT. Early TP53 testing is essential to guide the BC treatment plan.
引用
- Petry V, Bonadio RC, Moutinho K, et al. Frequency of Radiation Therapy-Induced Malignancies in Patients With Li-Fraumeni Syndrome and Early-Stage Breast Cancer and the Influence of Radiation Therapy Technique. Int J Radiat Oncol Biol Phys. 2024. PMID: 38309330. doi:10.1016/j.ijrobp.2024.01.204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。